BridgeBio Pharma BBIO
$76.03 −$2.15 (-2.75%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $76.03 0.00%
Open$77.85
Prev close$78.18
Day range$75.46 – $78.24
Volume1.48M
Market cap$14.81B
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±3.8%last 8 reports
Closed higher3 of 838% of the time
Best reaction+6.0%
Worst reaction-8.9%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 29 Oct 2026 | After Market | ±10.2% | +5.97% | Within range |
| 2026/Q2 | 10 Aug 2026 | After Market | ±7.2% | -1.15% | Within range |
| 2026/Q1 | 7 May 2026 | After Market | ±7.2% | -0.09% | Within range |
| 2025/Q4 | 24 Feb 2026 | After Market | ±11.0% | -2.59% | Within range |
| 2025/Q3 | 29 Oct 2025 | After Market | ±10.9% | -4.88% | Within range |
| 2025/Q2 | 5 Aug 2025 | After Market | ±14.5% | -8.94% | Within range |
| 2025/Q1 | 29 Apr 2025 | After Market | ±12.9% | +5.33% | Within range |
| 2024/Q4 | 20 Feb 2025 | Pre Market | ±14.7% | +1.42% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$353.17M+192.6% YoY
Operating profit-$11.64M+91.5% YoY
Net profit-$60.50M+67.3% YoY
Diluted EPS-$0.42+55.8% YoY
Free cash flow-$44.46M+60.5% YoY
Operating cash flow-$44.17M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin94.3%
Operating margin-37.3%
Net margin-62.6%
Return on assets-37.5%
Current ratio2.09
Liabilities / assets176.5%
Cash & investments$1.54B
Total debt$2.49B
Net cash (debt)-$953.20M
No comments yet — be the first to weigh in on BBIO.
Sign in to join the discussion.